The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Mechanism of action for air pollution-induced NSCLC
Charles Swanton, FRCP, BSc, PhD, Francis Crick Institute, London, UK, discusses the role of the air pollutant, particulate matter, in the development of non-small cell lung cancer (NSCLC) in never-smokers, as evaluated in the TRACERx trial (NCT01888601). In England, South Korea and Taiwan, increasing particulate matter levels were associated with increased risk of EGFR mutant NSCLC, providing evidence to limit air pollution and opportunities for molecular targeted cancer prevention. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
